Fat Cell Hormone Adiponectin
Weight Loss Without Affecting Appetite
Penn Discovery Opens up Potential
for Future Therapy to Tackle Obesity
(Philadelphia, PA) - Researchers at the University
of Pennsylvania School of Medicine have established
in an animal model that the hormone adiponectin secreted
by fat tissue acts in the brain to reduce body weight.
In contrast to leptin, a related hormone, adiponectin
can cause weight loss by raising metabolic rate while
not affecting appetite. This finding may have future
implications in understanding and treating obesity and
metabolic disorders like diabetes, says lead author,
Rexford Ahima, MD, PhD, Assistant Professor
of Medicine, Penn Diabetes Center. This research appears
in the May issue of Nature Medicine.
When adiponectin, which is involved in glucose and lipid
metabolism, was introduced into the cerebrospinal fluid
of normal mice, they showed no changes in food intake,
but their metabolism rose. “The animal burns off
more heat, so over time loses weight, which was very
fascinating because we knew that leptin caused weight
loss by suppressing appetite and increasing metabolic
rate,” explains Ahima. “Here we have another
fat hormone that can cause weight loss but without affecting
For many dieters, it’s easy, at first, to lose
weight; but over time, it becomes more difficult because
the body compensates, in part, by dropping its metabolic
rate. “Adiponectin or its targets in the brain
and other organs could be harnessed to sustain weight
loss by maintaining a high metabolic rate,” says
Ahima. “This is only a possibility. We’re
not suggesting at this point that adiponectin will become
a drug.” In severely obese mice, adiponectin rapidly
decreases blood glucose and lipids, while burning fat.
Hence, adiponectin could be beneficial in the treatment
of diabetes and heart disease associated with obesity.
These findings have far-reaching potential to help fight
the war against obesity, which healthcare experts agree
has reached epidemic proportions in the United States.
“For years people used to think fat tissue was
a passive player--just there to store excess energy,”
explains Ahima. This proved to be a simplistic view
since hormones produced by fat tissue are released into
the blood and are actively involved in the regulation
of metabolism. The best known fat hormone, leptin, decreases
body weight by decreasing appetite and increasing metabolic
rate. Leptin also reduces glucose and lipids. The researchers
found that both adiponectin and leptin require the melanocortin
pathway in the brain to control body weight and glucose.
However, these fat hormones also control metabolism
through other distinct pathways in the brain. “We
focus on the brain because it is a major coordinator
of feeding, metabolism, and hormones, including insulin,”
Other Penn researchers collaborating on this work are
Yong Qi, Nobuhiko Takahashi, and Hiralben R. Patel,
as well as Philipp E. Scherer, Anders Berg, and Utpal
B. Pajvani from the Albert Einstein College of Medicine
and Stanley M. Hileman from West Virginia University.
The research is funded by grants from the National Institutes
a printer friendly version of this release, click
PENN Medicine is a $2.5 billion enterprise dedicated to the related missions
of medical education, biomedical research, and high-quality
patient care. PENN Medicine consists of the University
of Pennsylvania School of Medicine (founded in 1765
as the nation’s first medical school) and the
University of Pennsylvania Health System (created in
1993 as the nation’s first integrated academic
Penn’s School of Medicine is ranked #2 in the
nation for receipt of NIH research funds; and ranked
#4 in the nation in U.S. News & World Report’s
most recent ranking of top research-oriented medical
schools. Supporting 1,400 fulltime faculty and 700 students,
the School of Medicine is recognized worldwide for its
superior education and training of the next generation
of physician-scientists and leaders of academic medicine.
Penn Health System consists of four hospitals (including
its flagship Hospital of the University of Pennsylvania,
consistently rated one of the nation’s “Honor
Roll” hospitals by U.S. News & World Report),
a faculty practice plan, a primary-care provider network,
three multispecialty satellite facilities, and home
health care and hospice.
Penn Medicine is one of the world’s leading academic medical centers, dedicated to the related missions of medical education, biomedical research, excellence in patient care, and community service. The organization consists of the University of Pennsylvania Health System and Penn’s Raymond and Ruth Perelman School of Medicine, founded in 1765 as the nation’s first medical school.
The Perelman School of Medicine is consistently among the nation's top recipients of funding from the National Institutes of Health, with $550 million awarded in the 2022 fiscal year. Home to a proud history of “firsts” in medicine, Penn Medicine teams have pioneered discoveries and innovations that have shaped modern medicine, including recent breakthroughs such as CAR T cell therapy for cancer and the mRNA technology used in COVID-19 vaccines.
The University of Pennsylvania Health System’s patient care facilities stretch from the Susquehanna River in Pennsylvania to the New Jersey shore. These include the Hospital of the University of Pennsylvania, Penn Presbyterian Medical Center, Chester County Hospital, Lancaster General Health, Penn Medicine Princeton Health, and Pennsylvania Hospital—the nation’s first hospital, founded in 1751. Additional facilities and enterprises include Good Shepherd Penn Partners, Penn Medicine at Home, Lancaster Behavioral Health Hospital, and Princeton House Behavioral Health, among others.
Penn Medicine is an $11.1 billion enterprise powered by more than 49,000 talented faculty and staff.